Aspo specifies its financial guidance for 2021 and provides preliminary information on its operating profit for the first half of the year
Aspo Plc
Inside information
August 4 2021at 09.45
Aspo specifies its financial guidance for 2021and provides preliminary information on its operating profit for the first half of the year
Aspo Plc will specify its guidance for the full year 2021 in view of market developments at the beginning of the second half and the revised market and demand outlook for businesses towards the end of the year.
New guidance
Aspo 's operating profit will be approximately EUR 30-36 million (19.3 million) in 2021.
Previous guidance (issued 11 February 2021)
Aspo’s operating profit in 2021 will be higher than in 2020 (EUR 19.3 million).
The financial guidance is specified due to increased industrial demand, which has further strengthened market environment of ESL Shipping and the positive development of transport volumes, especially among customers in the steel and forest industry. Telko's earnings development has also continued to be stronger than expected during the first half of the year.
Profit for the first half of the year
Aspo's operating profit for the first six months of the year is the highest in the company's history at EUR 17.5 million (H1/2020: EUR 8.1 million).
Aspo will publish its half-year financial report from 1 January to 30 June 2021 on Wednesday 11 August 2021.
ASPO Plc
Aki Ojanen
CEO
Further information:
Aki Ojanen, CEO
tel. +358 400 106 592, aki.ojanen@aspo.com
Aspo is a conglomerate that owns and develops business operations in Northern Europe and growth markets focusing on demanding B-to-B customers. Our strong company brands - ESL Shipping, Leipurin, Telko and Kauko - aim to be the market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these. Together they generate Aspo's goodwill. Aspo's Group structure and business operations are continually developed without any predefined schedules.
Distribution:
Nasdaq Helsinki
Key Media
www.aspo.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: openbaarmaking over transparantiekennisgeving19.4.2024 18:00:00 CEST | Press release
Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Attachment NL_transparency notification_20240419
23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release
Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di
Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding
Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release
Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and